The Council's lean
Across recent runs, the Council is strongly up for the next year (65% chance of rising, 5 calls).
How the twelve seats split (next year)
Each seat reads one kind of data. This is how each one leaned across those same calls.
| Seat | Leaned |
|---|---|
| Price Chart | 3 up, 2 down |
| Financials | 3 up, 1 down |
| Analyst Targets | 4 up, 1 down |
| Earnings Estimates | 5 up |
| Insider Trades | 1 up, 2 down, 2 even |
| Congress Trades | 5 up |
| News | 5 up |
| SEC Filings | 5 up |
| Institutional Holdings | 2 down, 3 even |
| Options Market | 2 up, 1 down, 2 even |
| Economy | 5 up |
| Related Markets | 5 up |
Every call is saved and scored later against what the price did: how calls are scored.
Questions
What do AI analysts think of AZN (AstraZeneca PLC)?
Across 5 recent calls, Ticker Council's twelve AI analysts lean strongly up on AZN for the next year (65% chance of rising). Each seat reads one kind of data, they debate, and every call is scored afterwards. Not financial advice.
Is AZN a buy?
Ticker Council doesn't say buy or sell. It shows which way the evidence leans and how sure the Council is. Right now: strongly up for the next year (65% chance of rising). Use it as a second opinion and decide for yourself. Not financial advice.
Not financial advice. These are AI analysts' leans, not instructions to buy or sell, and they can be wrong.